Intrinsiqq
Cara Therapeutics Inc. logo

Cara Therapeutics Inc.

TVRD

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$13M
EPS$0.15
P/E6.59
P/FCF–
EV/EBITDA0.32
FCF Yield–
Div. Yield–
Net Debt/FCF–
Cara Therapeutics Inc. intrinsic value
52-Week Range
$0.79$2.96

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$27M

▲ +38.0% YoY

Op. Margin

–

ROIC

-145.52%

▼ -34.4pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$27M

▼ -28.4% YoY

Net Debt

-$22M

Net Cash Position

Cash & Equiv.

$22M

5Y CAGR: -18.5%

Continue Research

Peers

Pharmaceutical Preparations · Pick stocks to compare with TVRD

CompareIntrinsic value
ALMSAlumis Inc.
$3.96-8.55%10
KZRKezar Life Sciences, Inc.
No recent price20
HCWBHCW Biologics Inc.
$0.75+1.90%15
ADAGAdagene Inc.
$1.76-12.44%25
RANIRani Therapeutics Holdings Inc.
$0.51-12.03%10
PULMPulmatrix Inc.
$1.28-10.21%40
COGTCogent Biosciences, Inc.
$26.72-3.70%20
ACRSAclaris Therapeutics, Inc.
$3.44-1.71%10

Cara Therapeutics (TVRD) in three numbers

Quality score
20/100
Best check: net debt, -$22M. Weakest: return on capital, -145.5%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
6.59
From the last twelve months of earnings.
Financials

Questions about Cara Therapeutics

Is Cara Therapeutics (TVRD) overvalued?

Cara Therapeutics trades at 6.59 times earnings. Intrinsiqq's fair value calculator has no opening value for TVRD, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Is Cara Therapeutics a high-quality business?

Cara Therapeutics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 7 checks computed from SEC filings. Its best check is net debt at -$22M, and its weakest is return on capital at -145.5%. The Quality tab shows every check against its target.

Does Cara Therapeutics (TVRD) pay a dividend?

No. Cara Therapeutics (TVRD) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in TVRD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing TVRD

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.